Stocks to Watch: Applovin, Disney, Galera Therapeutics
By Ben Glickman
AppLovin reported a better-than-expected profit in the second quarter as the company's sales rose. The software company posted net income of $80.36 million, or 22 cents a share, while analysts polled by FactSet expected earnings of 8 cents a share. Shares climbed 24% to $36.48 in after-hours trading.
Walt Disney said it would significantly raise prices for its Disney+ and Hulu streaming services as it looks to make its direct-to-consumer business profitable. The streaming segment's loss narrowed in the second quarter, posting a loss of $512 million compared with $1.06 billion a year earlier. Disney shares rose 2.7% to $89.87 in after-hours trading.
Galera Therapeutics said the Food and Drug Administration told the company that results for one of its drug candidates weren't enough to warrant approval. The company said it would reduce its workforce by 70% in order to extend its cash runway following the FDA's decision. Shares fell 82% to 41 cents in after-hours trading.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
August 09, 2023 19:55 ET (23:55 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
10 Top-Performing Dividend Stocks of the Month
-
Marathon Petroleum Earnings: No Change to Competitive Position, but Shares Look Expensive
-
Charlie Munger and How Not to Invest
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
After Earnings, Is AT&T Stock a Buy, a Sell, or Fairly Valued?
-
Mastercard Earnings: A Stable Environment Highlights the Firm’s Strengths
-
Pfizer Earnings: Solid Results Supported by Steady Tracking Toward $4 Billion In Cost Cuts
-
Starbucks Earnings: Not a Lot to Like About Results as Global Traffic Sputters